Data / Form D filings / Acerus Pharmaceuticals Corp
Acerus Pharmaceuticals Corp: Form D filings
Acerus Pharmaceuticals Corp, a pharmaceuticals company in Mississauga, Ontario, Canada, filed 3 Form D notices with the SEC between 2011 and 2016. The latest, on May 5, 2016, reports $2 million sold of a $2 million offering to 1 investor.
Find out what Acerus Pharmaceuticals Corp does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2486 DUNWIN DRIVE, Mississauga, Ontario, Canada, L5L 1
- Phone
- (416) 679-0771
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Ontario, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1527246
The full lists. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 5, 2016 | New notice | $2,000,000 | $2,000,000 | $0 | 1 | Apr 27, 2016 | sec.gov |
| Aug 13, 2014 | New notice | $2,131,268 | $2,131,268 | $0 | 2 | Jul 30, 2014 | sec.gov |
| Aug 3, 2011 | New notice | $12,026,355 | $6,847,846 | $5,178,509 | 16 | Jul 14, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| MATTHEW K. HAWKINS | Executive Officer | |
| IAN IHNATOWYCZ | Director | |
| BORYS K. CHABURSKY | Director | |
| ROLF K. REININGHAUS | Director | |
| TOM K. ROSSI | Executive Officer, Director | |
| JEFFREY K. SHERMAN | Director | |
| DR. NATHAN K. BRYSON | Executive Officer | |
| DR. MICHAEL K. BUMBY | Executive Officer | |
| STEPHEN GREGORY | Director | |
| JOSEF K. VEJVODA | Director | |
| NORMA BEAUCHAMP | Director |
Every Form D from the week of May 2, 2016 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Acerus Pharmaceuticals Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.